Researchers at the Intensive Care Unit of Hospital Metropolitano Doutor Célio de Castro retrospectively analyzed 178 adult patients who completed brain death protocols between December 2017 and December 2023. Of these, 141 patients underwent transcranial Doppler ultrasonography, or TCD, as the complementary exam, while 37 were evaluated with electroencephalography or cerebral angiography. The findings, published in the journal Neurocritical Care, show that TCD use was independently associated with a 53.9 percent reduction in the median time needed to complete the brain death protocol, a difference so large that it reshapes the logistics of end-of-life care and organ procurement.

The numbers are striking. In the TCD group, the median protocol duration was nine hours, with an interquartile range of five to twenty-three hours. In the non-TCD group, the median stretched to thirty-five hours, with an interquartile range of twenty to sixty-six hours. After adjusting for age, sex, comorbidity burden measured by the Charlson Comorbidity Index, illness severity measured by the Simplified Acute Physiology Score III, calendar year, and whether the protocol was opened during business hours or after hours, TCD use carried an incidence rate ratio of 0.46, meaning the protocol took less than half as long. The only other independent predictor of protocol duration was whether the process began during business hours, underscoring how staffing availability shapes this delicate timeline.

Transcranial Doppler ultrasonography is a bedside technique that uses low-frequency ultrasound pulses through the temporal bone and other acoustic windows to measure blood flow velocity in the major arteries of the circle of Willis, including the middle cerebral, anterior cerebral, and basilar arteries. The technique was first described in 1982, when researchers demonstrated that flow velocity in the basal cerebral arteries could be recorded noninvasively. In the context of brain death, rising intracranial pressure progressively exceeds the perfusion pressure, producing a characteristic sequence of Doppler waveforms: first a blunting of diastolic flow, then oscillating or reverberating flow in which blood moves back and forth with each heartbeat without net forward perfusion, then tiny systolic contraction spikes, and finally the disappearance of detectable flow altogether. Demonstration of these arrest patterns in both anterior and posterior circulations, on two examinations separated by an interval defined by national guidelines, provides evidence of cerebral circulatory arrest.

The diagnostic credentials of the technique are well established. A meta-analysis published in Intensive Care Medicine in 2006 reported high specificity for confirming brain death, and a subsequent systematic review and meta-analysis in the American Journal of Neuroradiology reached similar conclusions, with reported sensitivity around 88 percent and specificity approaching 98 percent in pooled analyses. Brazilian guidelines issued in 2012 formally endorsed transcranial ultrasound as a confirmatory test for brain death, and the country’s Federal Council of Medicine incorporated it into the regulatory framework through Resolution 2,173 of 2017. Unlike angiography, TCD requires no transport to a radiology suite, no iodinated contrast, and no exposure of potentially donor organs to nephrotoxic agents. Unlike electroencephalography, it does not require prolonged recording sessions or interpretation delays, and it sidesteps the technical confounders of electrical artifacts in the intensive care environment.

The efficiency gains extended beyond the protocol itself. Length of stay in the intensive care unit after protocol initiation was significantly shorter in the TCD group, with a median of one day compared with two days in the non-TCD group, and an adjusted incidence rate ratio of 0.51. In a health system where intensive care beds are chronically scarce and expensive, each day of occupancy by a patient who has already died by neurologic criteria carries an opportunity cost measured in the patients waiting for that bed. The researchers also examined whether the choice of confirmatory exam influenced organ donation, and found that it did not: donation rates were statistically indistinguishable between the groups, at 35 percent in the TCD group and 38 percent in the non-TCD group. Faster protocols, in other words, did not come at the expense of donation outcomes, though they also did not visibly increase them in this cohort.

The study’s statistical approach was deliberately conservative. Because protocol duration and length of stay are skewed, count-like variables, the team used negative binomial regression rather than ordinary linear models, adjusting for the full panel of demographic, clinical, and logistical covariates. The groups were comparable at baseline in age, comorbidity, severity scores, and sex, with all baseline comparisons showing no significant differences. Supplementary correlation analyses reinforced the main findings: TCD use and business-hours protocol opening showed the strongest negative correlations with protocol duration, while illness severity, age, and comorbidity played smaller or negligible roles. Notably, the underlying diagnoses differed between groups, with subarachnoid hemorrhage more frequent among patients who did not receive TCD, at 49 percent versus 26 percent, and ischemic stroke more frequent in the TCD group, at 28 percent versus 11 percent. This pattern likely reflects a practical reality of neurosonology: adequate acoustic windows are harder to obtain in some patients, and certain clinical scenarios push teams toward angiography or electroencephalography instead.

The authors are careful about the limits of their conclusions. This was a single-center, retrospective study at a Brazilian tertiary hospital where confirmatory testing is mandatory, and they caution that generalizability to settings without such requirements is limited. In countries where confirmatory tests are optional, the operational calculus differs, since the protocol can sometimes be completed with repeated clinical examinations alone. The findings also hinge on the availability of trained practitioners; TCD interpretation in the setting of suspected brain death demands specific expertise in recognizing the arrest waveforms and in distinguishing them from technical limitations such as poor insonation windows. The authors argue that their results support broader implementation of TCD in countries with mandatory confirmatory testing, contingent on that trained practitioner availability being secured.

The implications ripple outward to two of the most pressing issues in critical care. The first is organ donation, where every hour of delay increases the risk of hemodynamic instability, cardiac arrest, and loss of viable organs, and where families awaiting a definitive answer endure prolonged uncertainty at the bedside. The second is intensive care capacity, where protocols that conclude in nine hours rather than thirty-five return beds to the queue of critically ill patients faster. A bedside ultrasound exam that costs a fraction of a digital subtraction angiography study and requires no patient transport may thus be one of the highest-leverage tools available in the delicate interval between devastating brain injury and the formal pronouncement of death. As brain death determination frameworks worldwide undergo revision, including the recent consensus guideline from American neurologic and critical care societies, this Brazilian dataset offers a reminder that the operational details of how death is confirmed can matter almost as much as the criteria themselves.

Subject of Research: Use of transcranial Doppler ultrasonography as a confirmatory exam in brain death determination protocols

Article Title: Transcranial Doppler Ultrasonography as a Complementary Exam in Brain Death Determination: Impact on Protocol Duration and ICU Length of Stay—A Single-Center Study in Brazil

Article References: de Freitas, M. R., de Lima, A. F., & Coutinho, C. F. A. (2026). Transcranial Doppler Ultrasonography as a Complementary Exam in Brain Death Determination: Impact on Protocol Duration and ICU Length of Stay—A Single-Center Study in Brazil. Neurocritical Care. https://doi.org/10.1007/s12028-026-02641-w

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02641-w

Keywords: transcranial Doppler, brain death, brain death protocol, organ donation, intensive care unit, cerebral circulatory arrest, neurocritical care, TCD ultrasonography, ICU length of stay, Brazil, confirmatory testing, negative binomial regression

The clinical problem is rooted in simple mechanics. After traumatic impact, the spinal cord swells with edema and hemorrhage, yet it is confined within the rigid vertebral canal and an inelastic dural sac — a closed compartment with almost no room to spare. As pressure within the injured segment rises, it squeezes the small vessels supplying the cord from the outside, and blood flow falls. Starved of oxygen, neural tissue slides into a cascade of secondary injury: excitotoxic neurotransmitter release, mitochondrial failure, free radical generation, and progressive cell death that can convert a partial injury into a complete, permanent one. Guidelines already recognize the stakes, recommending elevated blood pressure targets after acute injury, because systemic perfusion is currently the only lever clinicians can pull. But without knowing the pressure inside the injured cord itself, every patient is treated with the same blunt instrument: push the mean arterial pressure up and hope. Neurosurgeons in the field have long argued that this is equivalent to managing traumatic brain injury without measuring intracranial pressure — a practice medicine abandoned decades ago after it became clear how dangerous flying blind could be.

The technology described in the new paper adapts a method proven in the brain. During the initial decompression and stabilization operation, surgeons insert a slim pressure transducer — essentially the strain-gauge technology long used for intracranial pressure monitoring — through the dura so that the sensor sits intrathecally at the injured cord segment. The device reports intraspinal pressure, the pressure within the dural tube surrounding the cord, continuously and in real time. From it flows a second, more meaningful number: spinal cord perfusion pressure, calculated as mean arterial blood pressure minus intraspinal pressure, a direct analogue of the cerebral perfusion pressure formula that anchors head-injury intensive care. Perfusion pressure is the driving force pushing blood through the cord’s microcirculation; when it falls too low, ischemia follows no matter how reassuring the systemic vital signs appear. Because the probe samples many times per second, clinicians can also derive indices of spinal cord autoregulation — the injured vasculature’s capacity to hold blood flow constant as blood pressure drifts. In earlier single-center work, higher intraspinal pressures and lower perfusion pressures tracked with worse neurological recovery, evidence that the measurements capture meaningful physiology rather than electronic noise.

Pressure is only the first layer of information. In most patients the teams added a microdialysis catheter: a fine hollow fiber tipped with a semipermeable membrane, perfused at an ultra-slow rate with sterile artificial cerebrospinal fluid. Small molecules in the injured cord’s extracellular space — glucose, lactate, pyruvate, glycerol, and the excitatory amino acid glutamate — diffuse across the membrane into the perfusate, which is collected in microvials changed at the bedside and analyzed. The lactate-to-pyruvate ratio serves as a sensitive flag for cellular energy failure, rising when mitochondria cannot exploit oxygen and cells fall back on anaerobic metabolism; glycerol signals membrane breakdown and cell death; glutamate marks excitotoxic stress. Roughly two in five patients in the new series also carried a third probe measuring tissue oxygen tension directly within the injured cord, converting the abstract idea of cord oxygenation into a number on a monitor. Together, the three probes turn the injury site into something closer to an instrumented organ: pressure, perfusion, oxygen, and metabolism, all sampled continuously through the most dangerous days after trauma.

What separates the new report — first authored by Love C. Ilochonwu — from earlier single-center studies is its scale and diversity. The analysis pooled experience from intensive care units at Aarhus University Hospital in Denmark, University Hospitals Leuven in Belgium, University Medical Centre Ljubljana in Slovenia, St George’s Hospital in London, and Hospital Universitario 12 de Octubre in Madrid. The researchers distributed a standardized questionnaire to all participating sites and retrospectively extracted each patient’s course from the medical record. The 109 adults had sustained acute, severe traumatic spinal cord injuries, and the cohort was severely affected: 58.7% were grade A on the American Spinal Injury Association Impairment Scale, meaning complete injury with no motor or sensory function preserved below the lesion; 19.3% were grade B, with sensory but no motor function spared; and 22.0% were grade C. The probes, placed during the initial surgery, stayed in situ for 5.3 ± 0.2 days on average — a window spanning precisely the period when cord swelling peaks and hemodynamic instability is most dangerous, and long enough to generate dense physiological datasets for every patient.

The results answer the two questions skeptics ask first: do the probes work, and do they stay where surgeons put them? Every patient received an intraspinal pressure probe; 67.9% also received microdialysis, and 44.0% also received an oxygen probe. Signal quality was rated good most of the time in 89.0% of patients for pressure, 95.9% for microdialysis, and 79.2% for oxygen — a performance envelope comparable to established neuromonitoring in the brain. Placement was verified with computed tomography in 89.0% of patients, and the scans confirmed good probe position in every case but one. That record matters, because a probe that has migrated or malpositioned measures the wrong tissue or nothing at all, silently corrupting the numbers on which clinical decisions would rest. The oxygen sensors were the least consistent of the three technologies, but they still delivered good signals most of the time in nearly four of every five patients — a respectable figure for instruments that must function inside a swollen, moving, metabolically hostile environment for close to a week.

Safety was the study’s central question, and the findings are reassuring with important caveats. The most common complication was cerebrospinal fluid leak, seen in 20.8% of patients — an expected consequence of passing a probe through the dura. Most leaks were straightforward to manage: 81.8% required only bedside suturing, 9.1% needed temporary lumbar drainage of cerebrospinal fluid to offload pressure, and 9.1% required early removal of the probe. Pseudomeningocele, a pocket of cerebrospinal fluid collecting beneath the wound, developed in 10.4% of patients; 81.8% of these were asymptomatic and needed nothing more than observation, while 18.2% required surgery. Wound infections occurred in 4.7% of patients, resolving with antibiotics alone in 60.0% of cases and requiring surgical debridement in the remainder. Set against these manageable events is what the team never observed across the entire cohort: not one case of spinal cord damage from the probes themselves, not one meningitis, not one spinal hematoma. In the authors’ conclusion, the main risks of intrathecal monitoring are CSF leak, pseudomeningocele, and wound infection — recognizable, treatable complications — while the feared catastrophic events simply did not occur.

The most provocative material concerns what the probes reveal at the bedside. Although the signals in this series were collected primarily for research, the authors present examples of their potential clinical value: real-time visualization of spinal cord perfusion pressure, of cord autoregulation, and of tissue oxygenation and metabolism. In practice, that means an intensivist can watch whether raising blood pressure with fluids and vasopressors genuinely improves perfusion of the injured segment, or whether the cord’s vessels have lost the capacity to respond. It can expose the patient whose perfusion pressure looks adequate on paper while microdialysis shows a climbing lactate-to-pyruvate ratio — tissue starving despite acceptable numbers. It can reveal oxygen desaturation within the cord that no systemic monitor would detect. Earlier work by the London group found that intraspinal pressure and perfusion pressure measured in the first days after injury predicted neurological outcome, lending the signals prognostic weight as well as physiological meaning. The parallel with neurocritical care for the brain is hard to miss: intracranial pressure monitoring helped transform traumatic brain injury from intuitive management into protocolized, physiology-guided care, and spinal cord monitoring now stands roughly where brain monitoring stood a generation ago.

The authors are candid about limits. This was a retrospective case series without a control group; it establishes feasibility, signal quality, and safety, not benefit. Whether patients managed with monitoring-guided perfusion targets recover more function than those managed conventionally is precisely the question that prospective trials must now answer, and the multi-center infrastructure demonstrated here looks like scaffolding for exactly those studies. Retrospective data can also under-ascertain complications, although the thoroughness of the safety accounting and the consistency of results across five institutions, five surgical teams, and five intensive care cultures argue that the technique is robust beyond any single expert center. The research was supported by the Marie Skłodowska-Curie Actions SOPRANI network, Wings for Life, UK Research and Innovation, and the UK National Institute for Health and Care Research. For the hundreds of thousands of people who sustain traumatic spinal cord injuries worldwide each year, the immediate message is narrow but significant: the tools to see inside the injured cord exist, they work in ordinary intensive care units, and their risk profile is now quantified. The era of treating the injured spinal cord as a black box may finally be closing.

Traditional monitoring of patients suffering from traumatic brain injuries (TBIs) and related neurological conditions such as hydrocephalus and brain hemorrhage often involves the placement of drainage systems to remove excess cerebrospinal fluid (CSF). Annually, approximately 25,000 patients in the United States alone require such interventions. A substantial subset of these cases, up to 20%, experience infections that exacerbate patient outcomes, prolong hospital stays, and result in severe complications including meningitis, neural degradation, permanent disabilities, and, in some cases, fatality. The challenge faced by clinicians has been the labor-intensive and infrequent sampling methods currently employed for infection detection.

Existing protocols rely primarily on intermittent sampling of cerebrospinal fluid, which is then sent to laboratory facilities for microbial and chemical analysis. This process inherently limits testing frequency to once every 24 to 48 hours, significantly delaying critical interventions. Addressing these constraints, the international consortium of researchers embarked on designing a system capable of continuous surveillance, providing granular data on the biochemical milieu within drainage lines without the need for repetitive invasive sampling.

Enter NeuroSense – a sophisticated monitoring device that integrates seamlessly into existing drainage infrastructure. Utilizing electrochemical sensor technology, NeuroSense monitors pivotal biomarkers such as glucose, lactate, and pH levels, all of which serve as early indicators of infection and physiological anomalies within the CSF. The system simultaneously tracks flow rate, an often overlooked but vitally important parameter, as deviations can signal malfunction or obstructions in drainage systems, further compromising patient health.

The compact design of NeuroSense, comparable in size to a modern smartphone, incorporates a 3D-printed housing that accommodates four highly sensitive sensors. These sensors interface with an electrochemical analyzer capable of processing signal transduction from biochemical changes rapidly and accurately. The results are displayed on an intuitive bedside monitor, granting physicians and nurses immediate access to actionable data and enabling rapid clinical decision-making.

Such real-time monitoring represents a paradigm shift in neurocritical care. The instantaneous feedback loop provided by NeuroSense ensures that emerging infections or drain anomalies are identified promptly, circumventing the historical delays intrinsic to laboratory testing. This technological breakthrough allows health-care providers to initiate targeted treatments sooner, thereby reducing complications, hospital length of stay, and overall health-care costs.

The development of NeuroSense was spearheaded by a multidisciplinary team featuring expertise from electrical and computer engineering, biomedical science, and clinical neurology. Dr. Mahla Poudineh, a professor at Waterloo and the Canada Research Chair in Health Monitoring BioNano Devices, highlighted the transformative potential of this system. Alongside PhD candidate Fatemeh Keyvani, who led much of the hands-on research development, the team validated the device’s performance through comparative laboratory experiments and preliminary clinical trials within intensive care units.

Initial validation involved rigorous benchmarking against standard cerebrospinal fluid testing methodologies. The system’s ability to detect shifts in glucose and lactate concentrations, both metabolic indicators sensitive to infection-related changes, demonstrated remarkable correlation with traditional diagnostic data. These findings were corroborated by pilot testing within hospital ICUs, where NeuroSense contributed valuable continuous data streams previously unattainable by conventional methods.

Looking forward, researchers aim to enhance NeuroSense’s clinical utility by incorporating automated alert mechanisms that can notify care teams instantly upon detection of critical deviations. This feature would not only optimize response times but also alleviate continuous manual monitoring burdens on medical staff. Furthermore, comprehensive multicenter clinical trials are planned to provide robust statistical validation and facilitate regulatory approval, propelling the device toward widespread commercial availability.

Critical collaboration underpinned this success, with researchers from renowned institutions including University Medicine Rostock in Germany, Massachusetts Institute of Technology, and Harvard Medical School contributing essential expertise. This international cooperation synergized engineering innovation with clinical insights, underscoring the multidisciplinary nature of modern biomedical engineering challenges.

The scientific community has recently acknowledged this work through publication in the prestigious journal Science Translational Medicine. The article, titled “A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care,” delineates the comprehensive design, testing, and clinical implications of the NeuroSense platform. It stands as a testament to the growing intersection of engineering and medicine, promising not only to enhance clinical outcomes but also to set new standards for patient monitoring technologies in critical care environments.

In summary, NeuroSense exemplifies the potential of advanced bioengineering to address longstanding clinical challenges by delivering a practical, efficient, and precise monitoring solution. It offers a beacon of hope for patients afflicted with traumatic brain injuries and related neurological conditions, where timely detection and management of complications such as infections can markedly influence recovery trajectories. As development proceeds, this technology is expected to become an indispensable component of neurocritical care protocols worldwide.

Subject of Research: Continuous Monitoring and Early Detection of Infections in Traumatic Brain Injury Patients

Article Title: A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care

News Publication Date: Not provided

Web References: https://www.science.org/doi/10.1126/scitranslmed.aeb1381

References: Science Translational Medicine (journal publication)

Image Credits: Not provided

Keywords

Brain injuries, Traumatic brain injury, Health care, Biomedical engineering, Neurocritical care, Cerebrospinal fluid monitoring, Infection detection, Electrochemical sensors, Hospital intensive care, Medical devices

The research team conducted a thorough retrospective analysis involving 761 patients within the subacute phase of ICH recovery. Distinctively, the cohort was divided into two groups: 504 individuals who developed pulmonary infections (PIs) and 257 who did not, providing a robust framework for investigating potential predictive factors. Their analytic approach began with univariate logistic regression to delineate preliminary risk indicators, followed by sophisticated variable selection through Least Absolute Shrinkage and Selection Operator (LASSO) regression, a method celebrated for its ability to refine predictive models by penalizing overfitting and selecting the most relevant predictors.

Upon isolating key variables, these candidates were integrated into a multivariate logistic regression model, culminating in the development of a comprehensive nomogram. This nomogram serves as a graphical tool that clinicians can utilize to estimate individual patients’ probabilities of concurrent pulmonary infection with remarkable precision. The model’s efficacy was quantified using the area under the receiver operating characteristic curve (AUC), a metric for discriminative power, alongside calibration curves and the Hosmer–Lemeshow goodness-of-fit test to ensure statistical fidelity and practical applicability.

The results were nothing short of extraordinary. The model demonstrated an impressive AUC of 0.901, with a 95% confidence interval ranging from 0.878 to 0.924, underscoring its exceptional discriminatory capacity between patients at high versus low risk for pulmonary infections. Additionally, calibration assessments confirmed a near-perfect agreement between predicted and observed outcomes, evidenced by a Hosmer–Lemeshow P-value of 0.982. At the optimal decision threshold for clinical application, the model yielded a positive predictive value (PPV) of 92.6%, indicating strong confidence in identifying true infection cases, alongside a negative predictive value (NPV) of 68.0%, confirming its utility in ruling out infection in lower-risk individuals.

Among the eight independent predictors integrated into the model are age, prophylactic antibiotic use, disturbance of consciousness, tracheotomy, dysphagia, duration of bed rest, nasal feeding, and procalcitonin levels. These variables encompass both intrinsic patient factors and clinical interventions, reflecting a nuanced understanding of the multifaceted nature of infection risk during neurorehabilitation. Of particular note is the inclusion of procalcitonin, a biomarker intimately linked to systemic bacterial infections, which lends a biological dimension to the predictive framework, enhancing its precision beyond purely clinical parameters.

The inclusion of prophylactic antibiotic use in the model is a revealing indicator of real-world clinical practice variances that may influence infection trajectories. Disturbance of consciousness and dysphagia are critical neurological impairments that increase vulnerability to aspiration-related infections, while tracheotomy and nasal feeding represent invasive airway interventions known to elevate infection risks. Moreover, the duration of bed rest is increasingly recognized as a modifiable risk factor linked to pulmonary complications, highlighting the potential for targeted rehabilitation strategies to mitigate infection likelihood.

Crucially, the researchers went beyond mere statistical validation. They employed decision curve analysis (DCA) to appraise the model’s clinical utility across a spectrum of threshold probabilities, demonstrating substantial net benefit. This insight is paramount for clinicians, indicating that employing the model in practice could enhance decision-making processes regarding prophylactic and therapeutic interventions, ultimately improving patient outcomes by facilitating early diagnosis and personalized care strategies.

This study’s implications extend to the optimization of intensive care workflows, where timely identification of at-risk convalescent ICH patients can prompt earlier respiratory support and antimicrobial stewardship. It also promises to reduce unnecessary antibiotic exposure, combating the global challenge of antimicrobial resistance by tailoring interventions to those who will most benefit. Additionally, the nomogram’s user-friendly format empowers physicians to incorporate multifactorial risk assessment seamlessly within electronic medical records and clinical rounds.

The innovative methodology outlined in this study bridges the gap between data science and bedside medicine. By harnessing LASSO regression—a statistical tool that elegantly sifts through multicollinearity and complex interdependencies among variables—the model achieves a balance of simplicity and power, rendering it both rigorous in development and practical in deployment. Such precision medicine approaches exemplify the future trajectory of neurocritical care, where quantifiable risk assessments will underpin bespoke therapeutic pathways.

Furthermore, the validation process fortifies the model’s credibility, having assessed both discrimination and calibration rigorously. The exceptionally high AUC attests to reliable stratification capabilities, while the near-ideal Hosmer–Lemeshow test outcome mitigates concerns about overfitting or misestimation. Together, these metrics bolster confidence in the model’s reproducibility in clinical environments beyond the initial study cohort, although future prospective multicenter validations would enhance generalizability further.

Contextually, pulmonary infections complicating ICH recovery pose a formidable barrier to rehabilitation and long-term functional independence. Prior to this investigation, predictive tools remained limited, often lacking comprehensive incorporation of critical neurological and clinical care variables. This seminal study not only fills that void but also equips multidisciplinary teams with evidence-based guidance to proactively address pulmonary complications, potentially reducing ICU lengths of stay and associated healthcare costs.

As the healthcare landscape increasingly embraces artificial intelligence and predictive analytics, this research exemplifies how integrating conventional clinical data with advanced statistical modeling can yield profoundly impactful prognostic tools. Its deployment in clinical settings promises to foster a paradigm shift from reactive to preventive strategies, ultimately enhancing survival rates and neurologic recovery trajectories in patients who have suffered intracerebral hemorrhages.

In conclusion, this newly developed nomogram stands at the forefront of translational medicine, marrying rigorous data-driven insights with clinical pragmatism. By accurately identifying ICH patients at heightened risk for concurrent pulmonary infections during recovery, it paves the way for individualized care, targeted interventions, and improved patient prognoses. The model heralds an era wherein tailored risk stratification informs every step of patient management, underscoring the essential role of innovative predictive tools in modern medicine’s evolving arsenal.

Subject of Research: Clinical prediction modeling of concurrent pulmonary infection risk in convalescent intracerebral hemorrhage patients

Article Title: Development and validation of a clinical prediction model for concurrent pulmonary infection in convalescent patients with intracerebral hemorrhage

Article References:
Xu, J., Han, X., Qi, Y. et al. Development and validation of a clinical prediction model for concurrent pulmonary infection in convalescent patients with intracerebral hemorrhage. BioMed Eng OnLine 24, 88 (2025). https://doi.org/10.1186/s12938-025-01425-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-025-01425-1